Printer Friendly

WISCONSIN PHARMACAL COMPANY REPORTS PROVISION FOR PATENT INFRINGEMENT LAWSUIT AND FINAL FOURTH QUARTER AND FISCAL 1991 RESULTS

 WISCONSIN PHARMACAL COMPANY REPORTS PROVISION FOR PATENT INFRINGEMENT LAWSUIT AND FINAL FOURTH QUARTER AND FISCAL 1991 RESULTS
 JACKSON, Wis., Jan. 10 /PRNewswire/ -- John A. Wundock R.Ph., president and CEO of Wisconsin Pharmacal Company, Inc. (NASDAQ: WPCI), reported that the company had deferred announcement of final results for its fiscal year ended Sept. 30, 1991 because the company anticipated that the trial judge in the patent infringement lawsuit would make a ruling on the Company's motions for a new trial or, alternatively, as to the damage amount prior to the date the company is required to file its annual report on Form 10-K with the Securities and Exchange Commission. As of January 9, 1992, the trial judge has not made such a rulilng. As a result, the company has recorded a $2,000,000 provision in its fourth quarter ended Sept. 30, 1991. The provision includes the original $1,400,000 judgement determined by the jury, possible interest, costs associated with the company's voluntary recall of the product and related legal and court costs.
 The company had previously announced that on Oct. 28, 1991 a verdict was returned against Wisconsin Pharmacal in a patent infringement lawsuit in which the plaintiff contended that the company's Baitmate Max product (which accounted for approximately 3 percent of the company's fiscal 1991 revenues) infringed the Plaintiff's patent. The verdict was for $1,400,000 and contained a finding of "willfulness" which permits the trial judge, in his discretion, to increase the judgment up to three times but does not require him to do so. The company has reformulated its Baitmate Max product and does not anticipate that sales will be materially affected by the reformulation.
 The $2,000,000 provision increased the company's fourth quarter 1991 loss to $2,059,427, or $0.63 per share compared to a loss of $307,725 or $0.10 per share for the fourth quarter of fiscal 1990. The fiscal 1991 net loss after the provision is $1,480,427 or $0.45 per share compared to net income of $68,275 or $0.03 per share for fiscal 1990.
 Wundrock further stated that the provision "in no way indicates that the company's position on the litigation has changed." Should the company not prevail with its motions, it intends to appeal to a higher court.
 WISCONSIN PHARMACAL COMPANY, INC.
 CONDENSED CONSOLIDATED PRELIMINARY OPERATING RESULTS(A)
 QUARTER ENDED SEPT. 30 FISCAL YEAR ENDED SEPT.30
 REVENUES 1991 1990 1991 1990
 Product Sales $2,189,294 $1,750,670 $13,050,294 $10,400,670
 Royalties 75,000 75,000 300,000 300,000
 Total 2,264,294 1,825,670 13,350,294 10,700,670
 Income (Loss) Before
 Extraordinary
 Charge $(2,059,427) $(57,725) $(1,480,427) $318,275
 Income (Loss) $(2,059,427) $(307,725) $(1,480,427) $68,275
 Weighted Average
 Number of Common
 and Commmon
 Equivalent Shares
 Outstanding 3,278,078 3,019,926 3,278,078 2,254,106
 Per Share
 Income (Loss)
 Before Extra-
 Ordinary Charge $(0.63) $(0.02) $(0.45) $0.14
 Income (Loss) $(0.63) $(0.10) $(0.45) $0.03
 NOTE: Included above as a charge to earnings are the following amounts of research and new product development expenditures related to REALITY
 $20,795 $134,194 $415,690 $238,244
 (A) -- Includes a $2,000,000 provision for the outstanding patent infringement verdict returned against the company, including related expenses.
 -0- 1/10/92
 /CONTACT: John A. Wundrock, president and CEO of Wisconsin Pharmacal, 414-677-4121/
 (WPCI) CO: Wisconsin Pharmacal Company, Inc. ST: Wisconsin IN: SU: ERN


KD -- NY071 -- 8815 01/10/92 17:45 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 10, 1992
Words:608
Previous Article:MACROVISION ANNOUNCES NEW VICE PRESIDENT OF VIDEOCINEMA SYSTEMS
Next Article:TGX PLAN OF REORGANIZATION APPROVED


Related Articles
WISCONSIN PHARMACAL COMPANY REPORTS RECORD INCREASE IN FOURTH QUARTER AND FISCAL 1991 REVENUE
WISCONSIN PHARMACAL ANNOUNCES PATENT LITIGATION SETTLEMENT
WISCONSIN PHARMACAL REPORTS FIRST QUARTER RESULTS
WISCONSIN PHARMACAL REPORTS RECORD REVENUE
WISCONSIN PHARMACAL ANNOUNCES NEW CHARTEX AGREEMENT ON FEMALE CONDOM AND THIRD QUARTER RESULTS
WISCONSIN PHARMACAL COMPANY, INC. REPORTS SECOND QUARTER OPERATING RESULTS
WISCONSIN PHARMACAL COMPANY REPORTS THIRD QUARTER OPERATING RESULTS
WISCONSIN PHARMACAL COMPANY, INC. REPORTS INCREASED FIRST QUARTER PROFITS AND REVENUES DUE TO LITIGATION SETTLEMENT
WISCONSIN PHARMACAL COMPANY, INC. REPORTS SECOND QUARTER OPERATING RESULTS
WISCONSIN PHARMACAL COMPANY, INC. REPORTS FOURTH QUARTER AND FISCAL 1995 OPERATING RESULTS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters